Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis
Unlike atherosclerotic traits, genetically proxied IL-6 signaling downregulation is not associated with clinical, imaging, or pathological manifestations of arteriolosclerotic cSVD. These genetic findings suggest that targeting IL-6 signaling is unlikely to yield effects on cSVD prevention comparable with those expected for atherosclerotic disease.
Authors
- Joseph Kamtchum‐Tatuene (ORCID: https://orcid.org/0000-0002-1041-4202)
- Larissa Ange Tchuisseu‐Kwangoua (ORCID: https://orcid.org/0000-0002-9591-6139)
- Marios K. Georgakis (ORCID: https://orcid.org/0000-0003-3507-3659)
- Hugh S. Markus (ORCID: https://orcid.org/0000-0002-9794-5996)
- Aleksey Shatunov (ORCID: https://orcid.org/0000-0002-2671-8040)
- Murad Omarov (ORCID: https://orcid.org/0000-0001-6126-8631)
Institutions
- Broad Institute (US)
- Université de Yaoundé I (CM)
- University of Cambridge (GB)
- Oxford Research Group (GB)
- LMU Klinikum (DE)
- University of Oxford (GB)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1161/jaha.124.041814
- Primary Topic
- Cerebrovascular and genetic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00